RA Capital sues ChemoCentryx after biotech company’s $3.9 billion sale to Amgen

The suit comes 19 months after the Peninsula biotech company was sold to Amgen for $3.9 million.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks